Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
CHICAGO Amgen has switched its $50 million Neulasta consumer advertising account from Havas’ Euro RSCG to Abelson-Taylor here, according to an agency representative.
The Chicago shop already handled professional medical duties on the brand, which helps cancer patients create more white blood cells. Along with the Neulasta assignment, Abelson-Taylor also picked up Amgen’s Aranesp brand, another cancer drug that helps the body produce red blood cells.
While the client spent nearly $50 million on advertising Neulasta, per Nielsen Monitor-Plus, Aranesp has had only minimal spending.
Euro
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in